Precision medicine is a personalized healthcare approach that uses genetic, environmental, and lifestyle factors for patient treatment. Crucially, targeted sequencing is key in this paradigm to identify specific genetic mutations and molecular biomarkers. The technique expedites the development of targeted therapies and confirms more effective and individualized treatments.
Targeted sequencing in precision medicine alludes to the precise analysis of specific genomic regions of diseases or treatment responses. Comparatively, targeted sequencing is unique in precision medicine. Unlike whole-genome or whole-exome sequencing, it concentrates on a subset of genes or regions for deeper, more accurate analysis at a reduced cost and time.
Although whole-genome sequencing provides a wide-ranging indication, it might comprise enormous amounts of data with ambiguous clinical significance. On the other hand, targeted sequencing focuses on clinically relevant regions for more actionable insights.
For instance, in cancer treatment, targeted sequencing can identify mutations in explicit oncogenes like BRCA1/2 for breast cancer, guiding personalized therapy choices. In pharmacogenomics, targeted sequencing of genes like CYP2C19 can predict individual responses to medications such as clopidogrel. Accordingly, it augments treatment efficacy and moderates adverse effects.
In oncology, targeted sequencing finds mutations in cancer cells absent in normal cells. It develops modified cancer treatments. For instance, identifying mutations in the BRCA1 and BRCA2 genes in breast cancer can promote PARP inhibitors, which are more effective in cancers with these mutations. Furthermore, targeted sequencing matures new drugs while revealing the molecular pathways disrupted by specific mutations. It guides pharmaceutical research toward targeted therapies.
In oncology, targeted sequencing finds mutations in cancer cells absent in normal cells. It develops modified cancer treatments. For instance, identifying mutations in the BRCA1 and BRCA2 genes in breast cancer can promote PARP inhibitors, which are more effective in cancers with these mutations. Moreover, targeted sequencing matures new drugs while revealing the molecular pathways disrupted by specific mutations. It guides pharmaceutical research toward targeted therapies.
Targeted sequencing helps study and treat rare genetic disorders. While focusing on specific genes or gene panels of a rare condition, clinicians can realize a more accurate diagnosis when traditional diagnostic methods fall short. For example, in diseases like Duchenne Muscular Dystrophy, sequencing the DMD gene provides insights into the type of mutation, which informs treatment and management tactics. This targeted approach boosts comprehension of these rare conditions and, thus, paves the way for developing specific therapies for better patient outcomes.
Explore GeneMind’s Targeted Sequencing Solutions and Cancer Panel NGS Solutions for Precision Oncology across routine diagnostics and advanced genomic profiling. A Comprehensive Cancer NGS Solutions from 30 to 580 Genes
You are welcome to reach out to our expert, Wei Rong.
EXPLORE MORE
